A detailed history of Kbc Group Nv transactions in Nuvalent, Inc. stock. As of the latest transaction made, Kbc Group Nv holds 1,230 shares of NUVL stock, worth $118,695. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,230
Previous 1,587 22.5%
Holding current value
$118,695
Previous $113,000 16.81%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 08, 2025

SELL
$59.32 - $79.68 $21,177 - $28,445
-357 Reduced 22.5%
1,230 $94,000
Q4 2024

Jan 22, 2025

BUY
$77.87 - $104.93 $46,877 - $63,167
602 Added 61.12%
1,587 $124,000
Q2 2024

Jul 17, 2024

BUY
$62.76 - $81.61 $17,070 - $22,197
272 Added 38.15%
985 $75,000
Q4 2023

Feb 13, 2024

BUY
$42.42 - $80.28 $30,245 - $57,239
713 New
713 $52,000

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $4.15B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Kbc Group Nv Portfolio

Follow Kbc Group Nv and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.